Search

Your search keyword '"Zeaiter, A"' showing total 85 results

Search Constraints

Start Over You searched for: Author "Zeaiter, A" Remove constraint Author: "Zeaiter, A" Topic medicine Remove constraint Topic: medicine
85 results on '"Zeaiter, A"'

Search Results

1. Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug–Drug Interaction Study

2. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)

3. Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study

4. Lurbinectedin in the treatment of relapsed small cell lung cancer

5. Clinical Presentation and Management of Severe Acute Renal Failure in McArdle Disease

6. Helicobacter pylori outer membrane vesicles induce expression and secretion of oncostatin M in AGS gastric cancer cells

7. Physician and Patient Perceptions of Physical Touch in Primary Care Consultations in Lebanon: A Qualitative Study

8. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

9. Chest Wall Reconstruction with a Bilayered Wound Matrix Mesh Following Toilet Mastectomy

10. A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors

11. Bartonella henselae in Ixodes ricinus Ticks (Acari: Ixodida) Removed from Humans, Belluno Province, Italy

12. Unexpected Gastric Ectopic Pancreas During Sleeve Gastrectomy: A Case Report

13. Lack of correlation of Brucella antibody titers with clinical outcomes and culture positivity of brucellosis

14. MA16.01 Subsequent Systemic Therapy After Lurbinectedin Discontinuation in Patients With Small-cell Lung Cancer

15. PL02.03 Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial

16. Extraction and Characterization of Inulin-Type Fructans from Artichoke Wastes and Their Effect on the Growth of Intestinal Bacteria Associated with Health

17. Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study

18. First Case of Identification of Candida kefyr and Pichia kluyveri in Lebanese Water

19. Acute Simultaneous Renal and Ovarian Vein Thrombosis Mimicking Renal Colic and Associated with Factor V Leiden: Case Report and Review of Literature

20. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment

21. Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer

22. Is the Prevalence of Equinus Foot in Cerebral Palsy Overestimated? Results from a Meta-Analysis of 4814 Feet

23. MO01.08 Phase 2 Basket Trial of Lurbinectedin in Second-line SCLC: Characteristics and Outcomes in Treatment Responders

24. MO01.10 Activity of Lurbinectedin in Second-line SCLC Patients Who Are Candidates for Platinum Rechallenge

25. Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced endometrial carcinoma

26. First-in-human study of PM14 in patients with advanced solid tumors

27. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer

28. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

29. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non–Small-Cell Lung Cancer

30. ENCORE: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs. crizotinib (CZ) in untreated advanced ALK+ NSCLC

31. Do Brucella Antibody Titers Correlate with Clinical Outcomes and Culture Positivity of Brucellosis?

32. MO01.09 Phase 2 Basket Trial of Lurbinectedin in Small-Cell Lung Cancer (SCLC): Analysis of Efficacy by Baseline Characteristics

33. Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy Subjects

34. Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

36. Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors: Updated results from a phase Ib-II trial

37. Pooled safety analysis of single-agent lurbinectedin versus topotecan (Results from a randomized phase III trial CORAIL and a phase II basket trial)

38. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

39. Synthesis of Carbon Integration Networks Coupled with Hydrate Suppression and Dehydration Options

40. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

41. Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer

42. Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial

43. Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer

44. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study

45. Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies

46. 138PD_PR Patient-reported outcomes (PROs) in ALEX: A phase III study of alectinib (ALEC) vs crizotinib (CRIZ) in non-small-cell lung cancer (NSCLC)

47. P1.12-03 Antitumor Activity of Single Agent Lurbinectedin in Patients with Relapsed SCLC Occurring ≥30 Days After Last Platinum Dose

48. Lurbinectedin (LUR) in combination with irinotecan (IRI) in patients (pts) with advanced solid tumours

49. Corrigendum to 'Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer' [Lung Cancer 121 (July) (2018) Pages 37–40]

50. Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial

Catalog

Books, media, physical & digital resources